What is iloprost?
Iloprost is the investigational study drug for the Aurora study. This study is testing the safety and effectiveness of intravenous (IV) iloprost in people with systemic sclerosis (SSc), who experience frequent, symptomatic Raynaud’s phenomenon (RP) attacks.
For this study, an attack is defined as at least 1-color change of the finger(s) (blue, white, or red) associated with at least 1 symptom (pain, numbness, tingling, and/or discomfort of the finger[s]).
What is an investigational study drug?
Investigational means that a study drug has not been approved for public use and can only be used for research studies. Some study drugs, like iloprost, have been approved for use in other countries but have not been approved for use in the United States by the Food and Drug Administration (FDA).
Have other people used iloprost?
Yes. Iloprost has been used for many years as an inhaler for pulmonary arterial hypertension (PAH), both in and outside of the United States. It has also been used as an intravenous (IV) therapy for severe, disabling RP outside the United States.
Learn more about SSc and symptomatic RP